Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK Study of 14C-Labeled Poziotinib in Cancer Patients
NCT03804515Phase 1Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jun 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of poziotinib in solid tumor, sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Maximum recovery of the radioactive dose in plasma, urine and feces at 1 year. Started Jun 2019; status: terminated.
02
Drugs
poziotinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03804515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03804515.